CG Life’s Post

2024 will be a year of changes in the life sciences industry. Talk with William Dull, Russell Allen, and Stephen Joseph at various events in San Francisco. Hear how clients are accelerating their timelines through a different approach. #biotech #medtech #medicaldevice

Are you Launch Ready? Reach out to ImpactBio... before the pack passes you by! Our solutions are fine-tuned to your needs so every aspect of your launch is running at optimal performance. #launchready #salesleadership #talentacquisition #operationalexcellence

Racing to Launch? Partner with ImpactBio... Before You Miss the Finish Line! Our customized solutions ensure your launch races ahead with speed and agility, crossing the finish line with confidence and success. #launchready #salesleadership #talentacquisition #operationalexcellence"

BIO International Convention was a huge opportunity and learning experience. My key takeaways from attending for the first time last week: 🍻 Satellite events are where the real value is. We spent time on the exhibition floor and at satellite events, and hands down, made more meaningful connections at satellite events. This was because most people on the conference floor were salespeople, and we were more focused on having conversations about the science and business problems. At events run by Bullpen and several other organizations we were able to meet with decision makers, founders, and investors that gave great insights we'll be taking home with us, and will ideally lead to partnerships and deals in the coming weeks. 💰 Commercialization is king. The founders and CXOs we met all had amazing scientific and technological innovations at the core of their companies, but the problems everyone was looking to solve were around money and market. How do you fund the science? How do you get it in the hands and bodies of users? How can we make the business growth align with the mission? When you're learning to be a scientist most of the emphasis is on the hard scientific problems, but once you step into the business of science, it's all about engineering human systems. 🤝 The best way to form relationships is in person. Ontologic was founded post-pandemic, and as a software company, most of our work can be done remotely. But when you're limited to a 1h virtual panel or a 30m zoom meeting you don't make the same personal connection that you do in person. I was so happy to run into friends coincidentally on the conference floor and have conversations I likely wouldn't have purposely sought out with people I just happened to meet at satellite events. It strengthens relationships in a very human way that isn't captured in a virtual setting, and I plan to make time for in-person social events as much as possible moving forward. Would love to hear others' takeaways!

BIO 2024 starts tomorrow, June 3. You'll find the G&L team at Booth 1218, and they're ready to tell you more about our innovative services and solutions built around your specific needs and goals. We're looking forward to seeing you there. #HealthcareAdvisors #RegulatoryAffairs #QualityAssurance #BIO2024

The final results of our #BIO2024 step competition are in. Technically, there is one more day of BIO, but we limited the competition to the three "heavy days". Jessica Davis wins bragging rights with over 50K steps (~21 miles) walked and sometimes ran during the show. Her victory embodies one of the pillars of Dynamk Capital's investment strategy - CONSISTENCY! A key message we heard this week at BIO was that companies are indeed seeing positive growth indicators. Those who circled the wagons the past 12-18 months and focused on their core business, like Dyanmk Capital's portfolio companies, are poised to capitalize in 2024. A special thanks to our partners who co-exhibited this year at BIO: CellFE RoosterBio Inc. Vernal Biosciences Virica Biotech #venturecapital #biomanufacturing #drugdiscovery #cellandgenemanufacturing

Ready to ride the regulatory wave at #BIO2024? Whether you are a seasoned pro or just dipping your toes in, our experts like Marcus Bravo, MA are ready to help you make a splash. Find us at Booth 1218 and learn more about how services and solutions can help you ride the tide of success. #HealthcareAdvisors #RegulatoryAffairs #QualityAssurance #BIO Dave Yungvirt, Nathalie Bouchard, Richard Edmunds, Kevin O'Beirne

Off to BIO next week? Curious about what else you can be doing to optimise the return on investment for your asset(s)? If so, send me a message and I will connect you with one of our Advisors who will be happy to meet and discuss further. #BIO2024

We were proud to be selected as one of the Fierce Biotech Fierce 15 2024 Honorees. We asked ourselves – what makes us fierce? Here is what our team said #7. We are caring: People at OMass care about each other as individuals, respecting and embracing our diverse experiences, backgrounds and perspectives. Really getting to know each other helps us feel connected and included. We are unselfish, appreciate each other and take time to help and support one another. Caring is a 360° thing, where team members care about each other, the company cares about us, and we care about the company. Read more about how OMassians are transforming lives together, our values and our team HERE: https://lnkd.in/ddaju6xf #innovation #biotech #drugdiscovery

Thrilled about tomorrow's session at BioFIT Event, where I'll moderate a panel on the dynamics of early-stage partnering. At BIO International Convention last June in Boston, it was remarkable to witness over 50% increase in pre-clinical assets compared to the previous year, a clear indicator of a booming era for science. However, over 200 biotechs are still trading below cash value, and there's been a noticeable dip in licensing deals. This trend could signal a shift in investor focus towards nurturing existing portfolio companies, while big pharma may lean towards acquiring late-stage assets at lower costs. Such dynamics potentially overshadow the funding for new, groundbreaking early-stage assets. Our panel, featuring Vanessa Carle, Robert de Jonge, Daniel Marshall, Antoine Khallouf and Jan-Philipp Kruse , will delve into these current market realities and their influence on deal-making. #BIOFIT2023